KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Assets (2019 - 2025)

Royalty Pharma's Other Non-Current Assets history spans 7 years, with the latest figure at $79.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 136.46% year-over-year to $79.3 million; the TTM value through Dec 2025 reached $79.3 million, up 136.46%, while the annual FY2025 figure was $79.3 million, 136.46% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $79.3 million at Royalty Pharma, down from $86.6 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $86.6 million in Q3 2025 and bottomed at $3.9 million in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $28.7 million (2023), against an average of $29.9 million.
  • The largest annual shift saw Other Non-Current Assets tumbled 83.99% in 2024 before it soared 717.89% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $4.1 million in 2021, then skyrocketed by 614.81% to $29.6 million in 2022, then plummeted by 77.99% to $6.5 million in 2023, then surged by 414.17% to $33.5 million in 2024, then skyrocketed by 136.46% to $79.3 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Other Non-Current Assets are $79.3 million (Q4 2025), $86.6 million (Q3 2025), and $85.5 million (Q2 2025).